Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2656 to 2670 of 9102 results

  1. Insulin efsitora alfa for treating type 2 diabetes [ID6499]

    In development Reference number: GID-TA11644 Expected publication date:  22 October 2026

    Technology appraisal guidance
    In development

  2. Severe mental illness guidance review

    In development Reference number: GID-NG10465 Expected publication date: TBC

    NICE guideline
    In development

  3. Camizestrant with palbociclib for untreated oestrogen receptor-positive HER2-negative metastatic breast cancer after adjuvant endocrine treatment [ID6534]

    Awaiting development Reference number: GID-TA11686 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Diabetes in pregnancy: management from preconception to the postnatal period - Managing type 1 diabetes (T1D) using hybrid closed loops (update)

    In development Reference number: GID-NG10450 Expected publication date:  20 August 2026

    NICE guideline
    In development

  5. Novel risk profiling technologies to guide adjuvant chemotherapy decisions in early breast cancer

    Awaiting development Reference number: GID-HTG10904 Expected publication date: TBC

    HealthTech guidance
    Awaiting development

  6. Mezigdomide with dexamethasone and carfilzomib for treating relapsed or refractory multiple myeloma after at least 1 line of treatment ID6513: consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

    We are listening to your views on this Technology appraisal guidance. Comments close 29 June 2026.

    Technology appraisal guidance
    In consultation

  7. Mezigdomide with dexamethasone and carfilzomib for treating relapsed or refractory multiple myeloma after at least 1 line of treatment ID6513

    Awaiting development Reference number: GID-TA11660 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Lisocabtagene maraleucel for treating relapsed or refractory mantle cell lymphoma [ID6695]

    Awaiting development Reference number: GID-TA11930 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Lutikizumab for treating moderate to severe hidradenitis suppurativa in people 12 years and over

    Awaiting development Reference number: GID-TA12446 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Zilovertamab vedotin in combination for treating relapsed or refractory diffuse large B-cell lymphoma

    Awaiting development Reference number: GID-TA12458 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Niraparib for treating newly diagnosed unmethylated glioblastoma

    Awaiting development Reference number: GID-TA12449 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. GNT0006 ATA-100 for treating FKRP-related limb girdle muscular dystrophy R9 [TSID12384]

    Awaiting development Reference number: GID-TA12009 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. VX-522 for treating cystic fibrosis unresponsive to CFTR modulators when there are 2 mutations in the CFTR gene [TSID12431]

    Awaiting development Reference number: GID-TA12478 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Depemokimab for treating eosinophilic granulomatosis with polyangiitis [TSID12383]

    Awaiting development Reference number: GID-TA12007 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Digital technologies to aid the scoring and interpretation of diagnostic sleep studies for obstructive sleep apnoea and rare sleep disorders: draft scope consultation

    We are listening to your views on this HealthTech guidance. Comments close 3 July 2026.

    In consultation